Key Highlights
- Third quarter Revenue was USD 19.16 million, against a USD 8.82 million estimate and USD 0.348 million a year earlier.
- Net loss per share was USD 0.14 against an estimate of USD 0.47 and USD 0.61 in the prior-year quarter.
- Cash and marketable securities were USD 643.1 million at September 30, with nine-month operating cash use of USD 109.6 million.
- The European Commission granted Marketing authorization for Ubeslo and Evlarco in September, with PREVAIL interim analysis scheduled.
What moved a development-stage cardiovascular company from USD 0.3 million of quarterly revenue to USD 19.2 million? The answer sits with its European partner. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) recognized USD 18.3 million of license revenue in the quarter after regulatory milestones were reached under its agreement with Menarini. The company reported a net loss of USD 17.4 million, against USD 72.0 million a year earlier, and a net loss per share of USD 0.14 against an estimate of USD 0.47.
Menarini Milestones Drive the Revenue Line
Revenue of USD 19.16 million compares with USD 0.348 million a year earlier. The company said the increase came largely from the regulatory milestones under the Menarini license, which produced the USD 18.3 million of license revenue. For the nine months, revenue was USD 25.9 million against USD 22.5 million, including USD 7.6 million from Supply agreements with Menarini.
The regulatory path behind those payments moved quickly. In July 2026 the European medicines committee adopted a positive opinion, and in September the European Commission granted marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib with ezetimibe). Management said Menarini is scheduled to launch both in Germany by the end of 2026, with decisions from Switzerland and the United Kingdom awaited later this year. Of the up to EUR 863 million in milestone payments available, EUR 46 million has been earned, EUR 16 million of it during the nine months.
Spending Rises Around Late-Stage Trials
Research and development expenses were USD 39.4 million against USD 31.0 million, an increase of 27%. The company attributed USD 6.1 million of the increase to clinical expenses as trials were started and others progressed, and USD 3.5 million to personnel costs, partly because medical affairs staff are now classified within research and development. Selling, general and administrative expenses were USD 24.0 million against USD 24.5 million.
Two non-operating items shaped the bottom line. A Fair Value change on warrants produced a gain of USD 23.1 million, against a loss of USD 23.8 million a year ago, and interest income was USD 5.2 million against USD 6.7 million.
Cash Position and Capital Resources
Cash, cash equivalents and marketable securities were USD 643.1 million at September 30. Net cash used in Operating Activities was USD 109.6 million over nine months, against USD 106.9 million in the same period of 2025, and the accumulated loss stood at USD 892.4 million. Management said the cash balance covers non-cancelable commitments to research and Manufacturing vendors, estimated at a maximum of USD 54.3 million due within one year and USD 11.8 million after that.
Metrics to Track
Revenue of USD 19.16 million sits alongside a net loss of USD 17.4 million and cash of USD 643.1 million. The EUR 46 million of Menarini milestones earned to date is set against up to EUR 863 million available in total.
Management named several dated items. The independent safety monitoring board is scheduled to review PREVAIL interim data in the fourth quarter of 2026, with a recommendation received in the first quarter of 2027; if the trial continues, the company targets completion by the end of 2027. Topline data from the RUBENS trial, which completed enrollment of 347 patients in August, is planned around year end 2026. The Phase 2b SPINOZA trial in pre-clinical Alzheimer's disease began in September 2026.






Please wait processing your request...